

SanaGen, InSphero and Sanquin Awarded with Eurostars Grant for a Breakthrough Gene Therapy, Poised to Become First "Cure" for Severe Alpha-1 anti-Trypsin (AAT) Deficiency (AATD)
In a notable collaboration that underscores the power of innovation in drug discovery, SanaGen and InSphero, alongside the renowned Sanquin research institute, have been awarded a 1.3 million euro grant for the ambitious project NOCAAVAAT.









